Thursday, July 3, 2025 7/3/2025

NCI Cancer Screening Research Network: Coordinating and Communication Center

Award Number: UG1CA286954
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/09/2024
PERIOD OF PERFORMANCE END DATE: 12/31/2027

Group Awards By:

View Award Description

NCI Cancer Screening Research Network: Coordinating and Communication Center - SUMMARY/ABSTRACT The promise of early detection to reduce the burden of cancer is an easily understood and highly desired intervention point in the cancer continuum. Recent developments of multicancer detection (MCD) technologies have fueled already strong interest in their use, well in advance of compelling data describing the impact of MCD-based screening on cancer mortality. In addition to limited data available on sensitivity and lead time to assess these MCD tests, the complexities of implementing them in a real-world clinical environment require careful evaluation to assess the frequency of achieving resolution of a positive MCD test (i.e., a specific cancer diagnosis), the nature, timeline and cost of those procedures, and the potential to increase cancer worry and health inequities. To help to address these critical caps in data, the Cancer Screening Research Network (CSRN) will be a cooperative group structure with the expertise, infrastructure and access to appropriate patient populations needed to provide high quality evidence on the value of MCD tests in real-world settings. The goal for the Vanguard phase is to design and conduct a randomized controlled feasibility trial of two promising MCD tests. The CSRN Communication and Coordinating Center (CCC) in conjunction with the CSRN Statistics and Data Management Center (SDMC) and the NCI will lead and support this critical national effort. Our specific objectives are to: (1) Provide exceptional scientific and clinical expertise in the design and implementation of multicenter cancer screening trials, and particularly randomized trials evaluating MCD assays. (2) Develop the organizational structure and administrative relationships to assure CSRN success. (3) Develop and maintain effective communication channels and materials to promote CSRN success (4) Support CSRN ACCESS sites in their recruitment and retention efforts. By these efforts, the CSRN will assess the feasibility of and establish the core infrastructure needed to conduct future full-scale trials of MCD tests and other cancer screening studies. Through the efforts of the Vanguard phase, the CSRN will create the infrastructure, data and learnings needed to support full-scale trials and additional observational studies of the most promising MCD tests and other cancer screening approaches.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $2,121,173 )
2025	2025	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	001	2	4/9/2025	SUPPLEMENT FOR EXPANSION	$616,000
2025	2025	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Control	000	2	12/17/2024	NON-COMPETING CONTINUATION	$1,354,656
2025	2025	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Control	002	2	5/30/2025	NON-COMPETING CONTINUATION	$150,517
														Subtotal = $2,121,173

Issue Date FY: 2024 ( Subtotal = $1,130,173 )
2024	2024	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Control	000	1	2/9/2024	NEW	$1,125,001
2024	2024	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Control	001	1	2/21/2024	NEW	$5,172
														Subtotal = $1,130,173

Grand Total All Awards = $3,251,346

Top

All Categories

About

Search

Reports

Data Submission

Award Information

NCI Cancer Screening Research Network: Coordinating and Communication Center

Award Number: UG1CA286954

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/09/2024

PERIOD OF PERFORMANCE END DATE: 12/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer